rs377544304
Variant summary
Our verdict is Pathogenic. The variant received 12 ACMG points: 12P and 0B. PP3PS3_ModeratePM2_SupportingPM3_StrongPM1PP4_Moderate
This summary comes from the ClinGen Evidence Repository: The NM_000152.5:c.1799G>A variant in GAA is a missense variant predicted to result in substitution of arginine by histidine at amino acid 600 (p.Arg600His).This variant has been reported in at least 7 patients including those with symptoms consistent with infantile onset Pompe disease, <10% GAA activity in muscle, and showing improvement on enzyme replacement therapy (PMID:15121988, 24715333); one patient identified on newborn screen with confirmatory GAA activity testing and showing cardiac hypertrophy and arrythmia on cardiac evaluation (PMID:33073007), three patients with features consistent with Pompe disease and GAA activity in the laboratory's affected range in dried blood spots or leukocytes (PMID:2267665, 33741225) (PP4_Moderate). Four patients are compound heterozygous for the variant and another variant in GAA, phase unknown, that has been classified a pathogenic by the ClinGen LSD VCEP including c.-32-13T>G (2 independent probands, PMIDs: 21967859, 2267665), c.2481+110_2646+39del) (2 independent probands, PMID:15121988, 24715333; PMID:2267665), and one homozygote (PMID:33073007) (PM3_Strong). In addition, two patients are compound heterozygous for the variant and another missense change, or c.1465G>A (p.Asp489Asn) (PMID:22711147) or c.1751A>C (p.His584Pro) (PMID:33741225). The allelic data from these patients will be used in the assessment of the other missense change and is not included here to avoid circular logic. The amino acid change was reported in additional patients but the cDNA changes were not provided and so the data is not included (PMID:10338092, 20033296).The highest population minor allele frequency in gnomAD is 0.00003 (1.30606 alleles) in the South Asian population, which is lower than the ClinGen LSD VCEP threshold (<0.001) for PM2_Supporting, meeting this criterion (PM2_Supporting).This variant alters the arginine at amino acid 600, a residue that crystallography studies have shown to be important important in the active site architecture and substrate binding of GAA, and therefore has been defined as a critical residue by the ClinGen LSD VCEP (https://www.biorxiv.org/content/10.1101/212837v1.full.pdf, PMID:29061980) (PM1).This variant results in <2% GAA activity when expressed in COS-7 and HEK 293 cells (PMID:19862843, 24715333), and was shown to be abnormally processed by Western blot analysis, with production of very little of the active 76 kDa form, when expressed in HEK293 cells (PMID:24715333). PS3_Moderate is applied based on two separate studies, one showing GAA deficiency and the other showing abnormal GAA processing (PS3_Moderate).The computational predictor REVEL gives a score of 0.967 which is above the threshold of 0.7, evidence that correlates with impact to GAA function (PP3).Three additional missense changes in the same codon have been reported in patients with Pompe disease. The classification of p.Arg600His will be used to to support the classification of the other variants c.1798C>T (p.Arg600Cys) (pathogenic based on classification by the ClinGen LSD VCEP), c.1799G>C (p.Arg600Pro) and c.1799G>T (p.Arg600Leu), and is not used here to avoid circular logic.There is a ClinVar entry for this variant (Variation ID: 370130) with 10 submitters classifying the variant as pathogenic and two as likely pathogenic.In summary, this variant meets the criteria to be classified as pathogenic for Pompe disease. GAA-specific ACMG-AMP crteria applied, as specified by the ClinGen LSD VCEP (Specification Version 2.0): PM3_Strong, PM1, PS3_Moderate, PP4_Moderate, PP3, PM2_Supporting.Classification approved by the ClinGen LSD VCEP on Oct 18, 2022). LINK:https://erepo.genome.network/evrepo/ui/classification/CA8815482/MONDO:0009290/010
Frequency
Consequence
NM_000152.5 missense
Scores
Clinical Significance
Conservation
Publications
- glycogen storage disease IIInheritance: AR Classification: DEFINITIVE, STRONG Submitted by: Genomics England PanelApp, ClinGen, Labcorp Genetics (formerly Invitae), G2P, Laboratory for Molecular Medicine
- glycogen storage disease due to acid maltase deficiency, infantile onsetInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
- glycogen storage disease due to acid maltase deficiency, late-onsetInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 12 ACMG points.
Variant Effect in Transcripts
ACMG analysis was done for transcript: NM_000152.5. You can select a different transcript below to see updated ACMG assignments.
RefSeq Transcripts
| Sel. | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| GAA | MANE Select | c.1799G>A | p.Arg600His | missense | Exon 13 of 20 | NP_000143.2 | P10253 | ||
| GAA | c.1799G>A | p.Arg600His | missense | Exon 14 of 21 | NP_001073271.1 | P10253 | |||
| GAA | c.1799G>A | p.Arg600His | missense | Exon 13 of 20 | NP_001073272.1 | P10253 |
Ensembl Transcripts
| Sel. | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| GAA | TSL:1 MANE Select | c.1799G>A | p.Arg600His | missense | Exon 13 of 20 | ENSP00000305692.3 | P10253 | ||
| GAA | TSL:1 | c.1799G>A | p.Arg600His | missense | Exon 14 of 21 | ENSP00000374665.3 | P10253 | ||
| GAA | c.1814G>A | p.Arg605His | missense | Exon 13 of 20 | ENSP00000603465.1 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD2 exomes AF: 0.0000121 AC: 3AN: 248322 AF XY: 0.00 show subpopulations
GnomAD4 exome AF: 0.00000958 AC: 14AN: 1460678Hom.: 0 Cov.: 33 AF XY: 0.00000826 AC XY: 6AN XY: 726680 show subpopulations
Age Distribution
GnomAD4 genome Cov.: 33
ClinVar
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at